Possible additional therapeutic uses of aromatase inhibitors

  • Barrington J. A. Furr
Part of the Milestones in Drug Therapy book series (MDT)


Several excellent chapters in this book describe the clinical utility of aromatase inhibitors in the treatment of breast cancer. It is true to say that use of third-generation aromatase inhibitors has had a major therapeutic impact: emerging clinical evidence for some of them shows that they can achieve superior efficacy to tamoxifen, the gold standard of endocrine care for more than two decades.


Endometrial Cancer Aromatase Inhibitor GnRH Agonist Endometrial Thickness Premature Ejaculation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmac Therap 25: 127–205CrossRefGoogle Scholar
  2. 2.
    Bowman A, Gabra H, Langdon SP, Lessells A et al. (2002) CA125 response is associated with oestrogen receptor expression in a Phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8: 2233–2239PubMedGoogle Scholar
  3. 3.
    Papadimitriou CA, Markaki S, Siapkarasw J, Vlachos G et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Oncology 66: 112–117PubMedCrossRefGoogle Scholar
  4. 4.
    Krasner CN, Debernado RL, Findley M, Penson R et al. (2005) Phase II trial of ansastrazole in Combination with Gefitinib in Women with Asymtomatic Mullerian Cancer. Proc Am Soc Clin Oncol Abstract 5063Google Scholar
  5. 5.
    Sasano H, Sata S, Ito K, Yajima A et al. (1999) Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer 6: 197–204PubMedCrossRefGoogle Scholar
  6. 6.
    Morsi H, Leers M, Nap M, Bjorklund V et al. (2000) Apoptosis and anti-apoptosis in oestrogenreceptor negative endometrial cancer cells in response to anastrozole, 4-hydroxytamoxifen and medroxyprogesterone acetate. Eur J Cancer 36(Suppl 4): 112–113PubMedCrossRefGoogle Scholar
  7. 7.
    Rose PG, Brunetto VL, Vanle L, Bell J et al. (2000) A phase II trial of anastrozole in advanced recurrent or persistent edometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 78: 212–216PubMedCrossRefGoogle Scholar
  8. 8.
    Berstein L, Maximov S, Gersgfeld E, Meshkova I et al. (2002) Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 105: 161–165PubMedGoogle Scholar
  9. 9.
    Ma BBY, Oza A, Eisenhauser E, Stanimir G et al. (2004) The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers — a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14: 650–658PubMedCrossRefGoogle Scholar
  10. 10.
    Reich O, Regauger S, Urdl W, Lahousen M et al. (2000) Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82: 1030–1034PubMedCrossRefGoogle Scholar
  11. 11.
    Reich O, Regauer S (2004) Aromatase expression in low-grade endometrial stromal sarcomas. A immunohistochemical study. Mod Pathol 17: 104–108PubMedCrossRefGoogle Scholar
  12. 12.
    Maluf FC, Sabbatini MD, Schwartz L, Xia J et al. (2001) Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 82: 384–388PubMedCrossRefGoogle Scholar
  13. 13.
    Leunen M, Breugelmans M, De Sutter PH, Bourgain C et al. (2004) Low grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole: case report. Gynecol Oncol 95: 769–771PubMedCrossRefGoogle Scholar
  14. 14.
    Spano JP, Soria JC, Kambouchner M, Piperno-Neuman et al. (2003) Long term survival of patients given hormonal therapy for endometrial stromal sarcoma. Med Oncol 94: 87–94CrossRefGoogle Scholar
  15. 15.
    Reich O, Regauer S (2005) Hormonal treatment with aromatase inhibitors for patients with endometrial sarcoma. Gynecol Oncol 98: 173–174PubMedCrossRefGoogle Scholar
  16. 16.
    Santen RJ, Petroni GR, Fisch MJ, Myers CE et al. (2001) Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 92: 2095–2101PubMedCrossRefGoogle Scholar
  17. 17.
    Smith MR, Kaufman D, George D, Oh WK et al. (2002) Selective aromatase inhibition for patients with androgen-independent prostate carcinoma: a Phase II study of letrozole. Cancer 95: 1864–1868PubMedCrossRefGoogle Scholar
  18. 18.
    Bonomo M, Mingrone W, Brauchli P, Hering F et al. (2003) Exemestane seems to stimulate growth in men with prostate carcinoma. Eur J Cancer 39: 2111–2112PubMedCrossRefGoogle Scholar
  19. 19.
    Grosh WW, Mueller S, Alexander BF, Caldwell SH et al. (1999) Anastrozole (A) treatment of patients (pts) with advanced unresectable hepatocellular carcinoma (HCC). Proc ASCO 18: 286a Abstract 1096Google Scholar
  20. 20.
    Mitwally MFM, Casper RF (2000) The aromatase inhibitor, Letrozole: a promising alternative for clomiphene citrate for induction of ovulation. Fertil Steril 74: S35–S37CrossRefGoogle Scholar
  21. 21.
    Mitwally MFM, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75: 305–309PubMedCrossRefGoogle Scholar
  22. 22.
    Al-Omari WR, Sulaiman WR, Al-Hadithi N (2003) Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Gynecol Obstet 85: 289–291CrossRefGoogle Scholar
  23. 23.
    Park WI, Shin SY, Yang JS, Lee JY (2004) Clinical outcomes of ovulation induction with aromatase inhibitor: Prospective randomised comparison with clomiphene citrate. J Obstet Gynaecol Res 30: 262 Abstract 8–19Google Scholar
  24. 24.
    Elnashar AM (2002) Current uses of aromatase inhibitors in gynecology. Middle East Fertil Soc J 7: 173–179Google Scholar
  25. 25.
    Fisher SA, Reid MD, Van Vugt DA, Casper RF (2002) A randomised double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal woman. Fertil Steril 78: 280–285PubMedCrossRefGoogle Scholar
  26. 26.
    Sammour A, Biljan MM, Tan SL, Tulandi T (2001) Prospective randomised trial comparing the effects of letrozole and clomiphene citrate on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation prior to intrauterine insemination. Fertil Steril 76: S110–S112CrossRefGoogle Scholar
  27. 27.
    Mousavi-Fatemi H, Kolibiankis E, Tournaye H, Camus M et al. (2003) Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Bio Med Online 7: 543–546CrossRefGoogle Scholar
  28. 28.
    El Helw B, El Sadek M, Matar H, Fouad S et al. (2002) Single dose Letrozole versus CC for superovulation prior to intrauterine insemination: a prospective randomised study. Hum Reprod 17: Abstract 73Google Scholar
  29. 29.
    Mitwally MFM, Casper RF (2002) Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 77: 776–780PubMedCrossRefGoogle Scholar
  30. 30.
    Mitwally MFM, Casper RF (2003) Aromatase inhibition reduced gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 18: 1588–1597PubMedCrossRefGoogle Scholar
  31. 31.
    Mitwally MFM, Casper RF (2004) Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynaecol Invest 11: 406–415CrossRefGoogle Scholar
  32. 32.
    Tsirigotis M, Prapas G, Pistofidis G, Tika M et al. (2002) Experience with the use of letrozole in patients with a history of poor ovarian response in previous assisted reproductive cycles. Hum Reprod 17: Abstract 34Google Scholar
  33. 33.
    Healey S, Lin Tan S, Tulandi T, Biljan MM (2003) Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril 80: 1325–1329PubMedCrossRefGoogle Scholar
  34. 34.
    Casper RF (2003) Letrozole: ovulation or superovulation? Fertil Steril 80: 1335–1337PubMedCrossRefGoogle Scholar
  35. 35.
    Noble LS, Simpson ER, Johns A, Bulun SE (1996) Aromatase expression in endometriosis. J Clin Endocr Metab 81: 174–179PubMedCrossRefGoogle Scholar
  36. 36.
    Kitawaki J, Noguchi T, Amatsu T, Maeda K et al. (1997) Expression of aromatse cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but in normal endometrium. Biol Reprod 57: 514–519PubMedCrossRefGoogle Scholar
  37. 37.
    Bulun SE, Yang S, Fang Z, Gurates B et al. (2001) Role of of aromatase in endometrial disease. J Steroid Biochem Mol Biol 79: 19–25PubMedCrossRefGoogle Scholar
  38. 38.
    Takayama K, Zeitoun K, Gunby RT, Sasano H et al. (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69: 709–713PubMedCrossRefGoogle Scholar
  39. 39.
    Zeitoun K, Takayama K, Gunby RT, Carr BR et al. (1998) Treatment of severe endometriosis with an aromatase inhibitor: A novel indication and its molecular basis. J Soc Gynecol Invest 5(Suppl): 96aCrossRefGoogle Scholar
  40. 40.
    Razzi S, Fava A, Sartini A, De Simone S et al. (2004) Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomized woman. Br J Obstet Gynaecol 111: 182–184Google Scholar
  41. 41.
    Scarpellini F, Sbracia M (1998) Aromatase Inhibitors in the treatment of severe endometriosis. Fertil Steril 70(Suppl 1): Abstract 009Google Scholar
  42. 42.
    Scarpellini F, Sbracia M (2000) Aromatase inhibitors in the treatment of severe endometriosis. Proc ESHRE Abstract O-097Google Scholar
  43. 43.
    Scarpellini F, Sbracia M (2000) Aromatase inhibitors in the treatment of low responder women with severe endometriosis. Fertil Steril 72(Suppl): Abstract P-384Google Scholar
  44. 44.
    Ailawadi RK, Jobanputra S, Kataria M, Gurates B et al. (2004) Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 81: 290–296PubMedCrossRefGoogle Scholar
  45. 45.
    Soysal S, Soysal ME, Ozer S, Gul N et al. (2004) The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomised trial. Hum Reprod 19: 160–167PubMedCrossRefGoogle Scholar
  46. 46.
    Shippen ER, West WJ (2004) Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 81: 1395–1398PubMedCrossRefGoogle Scholar
  47. 47.
    Klemi P, Alanen K, Hietanen S, Grenman S et al. (2003) Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy. Obstet Gynecol 102: 1155–1158PubMedCrossRefGoogle Scholar
  48. 48.
    Turner KJ, Morley M, Atanassova N, Swanston ID et al. (2000) Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocr 164: 225–238PubMedCrossRefGoogle Scholar
  49. 49.
    Raman JD, Schlegel PN (2002) Aromatase inhibitors for male infertility. J Urol 167: 624–629PubMedCrossRefGoogle Scholar
  50. 50.
    Holbrook JM, Cohen PG (2003) Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation. South Med J 96: 544–547PubMedCrossRefGoogle Scholar
  51. 51.
    Leder BZ, Rohrer JL, Rubin SD, Gallo J et al. (2004) Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocr Metab 89: 1174–1180PubMedCrossRefGoogle Scholar
  52. 52.
    Finkelstein JS, Neer RM, Beverley MD, Biller MK et al. (1992) Osteopenia in men with a history of delayed puberty. N Engl J Med 326: 600–604PubMedCrossRefGoogle Scholar
  53. 53.
    Uruena M, Pantsiotou S, Preece MA, Stanhope R (1992) Is testosterone therapy for boys with constitutional delay of growth and puberty associated with impaired final height and suppression of the hypothalamo-pituitary-gonadal axis? Eur J Pediatr 151: 15–18PubMedCrossRefGoogle Scholar
  54. 54.
    Stanhope R, Brook CGD (1985) Oxandrolone in low dose for constitutional delay of growth and puberty in boys. Arch Dis Child 60: 379–381PubMedCrossRefGoogle Scholar
  55. 55.
    Carani C, Qin K, Simoni M, Faustini-Fustini M et al. (1997) ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337: 91–95PubMedCrossRefGoogle Scholar
  56. 56.
    Bilezikian JP, Morishima A, Bell J, Grumbach MM (1998) Increased bone mass as a result of oestrogen therapy in a man with aromatase deficiency. N Engl J Med 339: 599–603PubMedCrossRefGoogle Scholar
  57. 57.
    Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E et al. (2001) A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 357: 1743–1748PubMedCrossRefGoogle Scholar
  58. 58.
    Dunkel L, Wickman S (2002) Novel treatment of delayed male puberty with aromatase inhibitors. Horm Res 57(Suppl 2): 44–52PubMedCrossRefGoogle Scholar
  59. 59.
    Raivio T, Dunkel L, Wickman S, Janne OA (2004) Serum androgen bioactivity in adolescence: a longitudinal study of boys with constitutional delay of puberty. J Clin Endocr Metab 89: 1188–1192PubMedCrossRefGoogle Scholar
  60. 60.
    Zhou P, Shah B, Prasad K, David R (2005) Letrozole significantly improves growth potential in a pubertal boy with growth hormone deficiency. Pediatrics 115: E245–E249PubMedCrossRefGoogle Scholar
  61. 61.
    Wickman S, Kanjantie E, Dunkel L (2003) Effects of suppression of oestrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocr Metab 88: 3785–3793PubMedCrossRefGoogle Scholar
  62. 62.
    Wickman S, Saukkonen T, Dunkel L (2002) The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450 aromatase inhibitor. Eur J Endocr 146: 339–346CrossRefGoogle Scholar
  63. 63.
    Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocr Metab 85: 2370–2377PubMedCrossRefGoogle Scholar
  64. 64.
    Mauras N, Hayes V, O’Brien KO (2000) Estrogen treatment and estrogen suppression: metabolic effects in adolescence. J Paediatr Endocr Metab 13: 1431–1437Google Scholar
  65. 65.
    Roth C, Freiberg C, Zappel H, Albers N (2002) Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright Syndrome. J Paediatr Endocr Metab 15(Suppl 3): 945–948Google Scholar
  66. 66.
    Braunstein G (1993) Gynecomastia. N Engl J Med 328: 490–495PubMedCrossRefGoogle Scholar
  67. 67.
    Riepe FG, Baus I, Wiest S, Krone N et al. (2004) Treatment of pubertal gynaecomastia with the specific Aromatase Inhibitor Anastrozole. Horm Res 62: 113–118PubMedCrossRefGoogle Scholar
  68. 68.
    Plourde PV, Reiter EO, Jou H-C, Desrochers PE et al. (2004) Safety and efficacy of Anastrozole for the treatment of pubertal gynecomastia: a randomised, double-blind, placebo-controlled trial. J Clin Endocr Metab 89: 4428–4433PubMedCrossRefGoogle Scholar
  69. 69.
    Saltzstein D, Cantwell A, Sieber P, Ross JR et al. (2002) Prophylactic tamoxifen significantly reduced the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU International 90(Suppl 2): 120–121Google Scholar
  70. 70.
    Boccardo F, Rubagotti A, Garofalo L, Di Tonni P et al. (2003) Tamoxifen (T) is more effective than anastrozole (A) in preventing gynaecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts). ASCO Proc 22: 400 Abstract 1608Google Scholar
  71. 71.
    Conti G, Cretarola E, Boccardo F, Battaglia et al. (2004) Tamoxifen is safe and effective in preventing gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer and does not alter treatment efficacy. Eur Urol (Suppl) 3: 58Google Scholar
  72. 72.
    Knight JS, Satchidanand R, Cummings MH, Jackson A et al. (2004) A double-blind, randomised, controlled trial to evaluate the effect of anastrozole for the treatment of non-toxic multinodular goitre. Br J Surg 91(Suppl 1): 57Google Scholar
  73. 73.
    Knight HS, Yagat R, Yiangou C, Jackson A (2004) A double blind randomised controlled trial to evaluate the effect of anastrozole on non-toxic multinodular goitre. Clin Sci 106: 9PGoogle Scholar
  74. 74.
    Eshet R, Maor G, Ben Ari T, Eliezer MB et al. (2004) The aromatase inhibitor letrozole increases epiphyseal growth plate height and tibial length in peripubertal male mice. J Endocrinol 182: 165–172PubMedCrossRefGoogle Scholar
  75. 75.
    Shih C, Pan MH, Chu P (2000) Effects of estradiol and testosterone/proscar/arimidex on ORX-induced osteopenia in aged rats. J Bone Min Res 15: S343Google Scholar
  76. 76.
    Goss PE, Qi S, Josse RG, Pritzker ?? et al. (2004) The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34: 384–392PubMedCrossRefGoogle Scholar
  77. 77.
    Goss PE, Thomson T, Banke-Bochita J, Lowery C et al. (2002) A randomised placebo-controlled explorative study to investigate the effect of low oestrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12 week treatment with exemestane or letrozole. Breast Cancer Res Treat 76(Suppl 1): S76Google Scholar
  78. 78.
    Baum M, Budzar AU, Cuczick J, Forbes J et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomised trial. Lancet 359: 2131–2139 (Erratum, Lancet 360: 1520)PubMedCrossRefGoogle Scholar
  79. 79.
    Eastell R, Adams J (2002) Results of the ‘Arimidex’ (anastrozole, A), tamoxifen (T), alone or in combination (C ) (ATAC) trial: effects on bone mineral density (BMD) and bone turnover. Ann Oncol 13(Suppl 5): 32Google Scholar
  80. 80.
    Wojtacki J, Zielinski KW, Lesniewski-Kmak K, Wiraszka R et al. (2003) Effect of anastrozole therapy on bone: preliminary results of digital radiometrical analysis of clavicle and rib. Eur J Cancer (Suppl 1): S120Google Scholar
  81. 81.
    Lai JM, Taxel P, Raisz LG (1998) The effect of aromatase inhibition on bone turnover in older men. J Am Ger Soc 46: S79Google Scholar
  82. 82.
    Taxel P, Kennedy DG, Fall PM, Willard AK et al. (2001) The effect of aromatase inhibition on sex steroids, Gonadotropins, and markers of bone turnover in older men. J Clin Endocr Metab 86: 2869–2874PubMedCrossRefGoogle Scholar
  83. 83.
    Leder BZ, Rohrer JL, Rubin SD, Gallo J et al. (2003) Aromatase inhibition does not alter bone turnover, serum OPG or bone density in elderly men with mild hypogonadism. J Bone Min Res 18(Suppl 2): S42Google Scholar
  84. 84.
    Goss PE, Ingle JN, Martino S, Rober NJ et al. (2003) A randomised trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802PubMedCrossRefGoogle Scholar
  85. 85.
    Harper-Wynne C, Ross G, Sacks N, Dowsett M (2001) A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res Treat 69: 225Google Scholar
  86. 86.
    ATAC Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98: 1802–1810CrossRefGoogle Scholar
  87. 87.
    Coombes R, Hall E, Gibson LJ, Paridaens R et al. (2004) A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092PubMedCrossRefGoogle Scholar
  88. 88.
    Howell A, Cuzick J (2005) Vascular effects of aromatase inhibitors; data from clinical trials. J Steroid Biochem Mol Biol 95: 143–149PubMedCrossRefGoogle Scholar
  89. 89.
    Sawada S, Sato K (2003) Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat 82(Suppl 1): S31–S32Google Scholar
  90. 90.
    Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B et al. (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510–1513PubMedCrossRefGoogle Scholar
  91. 91.
    Harper-Wynne C, Ross G, Sacks N, Salters J et al. (2002) Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11: 614–621PubMedGoogle Scholar
  92. 92.
    Engen T, Krane J, Johannessen DC, Lonning PE et al. (1995) Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36: 287–297CrossRefGoogle Scholar
  93. 93.
    Lohrisch C, Paridaens R, Dirix LY, Beex L et al. (2001) No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane (E) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organisation of Research and Treatment of Cancer. (Breast Group) trial with exemestane. Proc Am Soc Clin Oncol 20: 43aGoogle Scholar
  94. 94.
    Atalay G, Dirix L, Biganzoli L, Beex L et al. (2004) The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 1095, “randomised phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients”. Ann Oncol 15: 211–21PubMedCrossRefGoogle Scholar
  95. 95.
    Cherrier MM, Asthana S, Plymate S, Baker LD et al. (2000) Cognitive effects from exogenous manipulation of testosterone and estradiol in older men. Soc Neurosci 26: 13Google Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Barrington J. A. Furr
    • 1
  1. 1.Global DiscoveryAstraZenecaMacclesfield, CheshireUK

Personalised recommendations